8-methoxy-4-(1H-pyrazol-4-yl)-2-quinazolinylamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-methoxy-4-(1H-pyrazol-4-yl)-2-quinazolinylamine
• 英文别名: 8-Methoxy-4-(1H-pyrazol-4-yl)-2-quinazolinamine；8-methoxy-4-(1H-pyrazol-4-yl)quinazolin-2-amine
• 化学式: C₁₂H₁₁N₅O
• 分子量: 241.252
• InChiKey: ZSQLEEXAPNWSGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  89.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  8-methoxy-4-(1H-pyrazol-4-yl)-2-quinazolinylamine 、 3-(Bromomethyl)-1-(1-methylethyl)-2(1h)-pyridinone 在 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 15.0h， 以10%的产率得到3-{[4-(2-amino-8-methoxy-4-quinazolinyl)-1H-pyrazol-1-yl]methyl}-1-isopropyl-1H-pyridin-2-one
  参考文献：
  名称：

  WO2020023846A5

  摘要：

  公开号：

  WO2020023846A5
• 作为产物：
  描述：

  2-氨基-3-甲氧基苯甲酸 在 盐酸 、 异丙基氯化镁 、 溶剂黄146 作用下， 以 四氢呋喃 、 甲醇 、 异丙醇 为溶剂， 反应 53.25h， 生成 8-methoxy-4-(1H-pyrazol-4-yl)-2-quinazolinylamine
  参考文献：
  名称：

  WO2018204661A5

  摘要：

  公开号：

  WO2018204661A5

文献信息

• Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US11045472B2

  公开（公告）日：2021-06-29

  Compounds of Formula I that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了可抑制 A2A 和 A2B 腺苷受体中至少一种受体的式 I 化合物，以及含有式 I 化合物的组合物和式 I 化合物的合成方法。 还描述了此类化合物和组合物用于治疗各种疾病、失调和病症的用途，包括至少部分由腺苷 A2A 受体和/或腺苷 A2B 受体介导的癌症和免疫相关疾病。
• QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US20200069689A1

  公开（公告）日：2020-03-05

  Compounds that inhibit at least one of the A 2A and A 2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A 2A receptor and/or the adenosine A 2B receptor.
• [EN] PYRIDONE A2R ANTAGONISTS<br/>[FR] ANTAGONISTES DE PYRIDONE A2R
  申请人：ARCUS BIOSCIENCES INC

  公开号：WO2020023846A1

  公开（公告）日：2020-01-30

  Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
• WO2018204661A5
  申请人：——

  公开号：WO2018204661A5

  公开（公告）日：2022-08-12
• WO2020023846A5
  申请人：——

  公开号：WO2020023846A5

  公开（公告）日：2022-08-01